Publication | Closed Access

Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance

Egfr-tki ResistanceMedicineLung AdenocarcinomaBronchial NeoplasmTumor SuppressorRadiation OncologyOncologyCell BiologyLung CancerTumor Biology